You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The framework is meant to guide healthcare providers in facilitating prostate cancer genetic testing in a timely and responsible way, the researchers said.
While Sera's previous validation work focused on the 37 and 35 week time points, the 32 week mark is perhaps most crucial in terms of patient outcomes.
New data shows that the test could eventually be useful in helping younger women avoid chemotherapy in the neoadjuvant setting.
The net proceeds will support continued product development, research, product commercialization, working capital, and other general corporate purposes.
The study aims to enroll 20,000 existing Biobank participants, as well as their adult children and grandchildren, from England, Scotland, and Wales.
The platform was used to subtype patients in a Phase II trial and found that patients in the claudin-low subgroup had the best two-year progression-free survival on pembrolizumab.
Bio-Rad said it is withdrawing its previously issued annual revenue guidance given the uncertainties regarding the duration and impact of the COVID-19 pandemic.
The San Diego-based genome mapping firm's share price fell below $1.00 for 30 consecutive days, triggering a noncompliance notification from Nasdaq.
The alliance will initially focus on rheumatoid arthritis using biomarkers discovered using Nimble's human proteome immunoprofiling technology.
First quarter revenue growth was driven by "unprecedented demand" for molecular biology products for use in COVID-19 testing.
The approach uses activity-based nanosensor technology being commercialized by spin-out Glympse Bio to detect dysregulated protease activity linked to disease.
The company will use the funds to expand its clinical genomic testing efforts into additional towns and cities in India, and accelerate its drug discovery programs.
The company reported total revenues of $1.31 million, up from $922,000 in Q4 2018, and 3,854 OVA1 sales, up 93 percent from 1,996 a year ago.
The firm is planning a prospective trial for the test after results in a small retrospective study showed good performance in identifying cancers and precancers.
The consortium is developing a real-time PCR test for host detection assays targeting epigenetic signatures and viral RNA for early-stage monitoring of potentially infected individuals.
Launched by 454 Founder Jonathan Rothberg and backed by $150 million in funding, the firm is the latest of several outfits to pursue protein sequencing.
The findings suggest blood-based testing for tau brain deposits is feasible and could be combined with other blood-based assays to improve Alzheimer's testing.
The company posted Q4 revenues of $15.9 million, up from $10.9 million in Q4 2018, and beat the consensus Wall Street estimate of $14.2 million.
The consortium aims to develop assays that can detect biomarkers of pulmonary fibrosis that can be used as early indicators of a treatment's activity.
Called Proclarix, the test combines the levels of two proteins with free and total PSA and patient age to assess risk of clinically significant prostate cancer.